New findings revealed a temporal association between the increasing incidence of endometrial cancer and obesity, with a disproportionate impact on younger women and minority populations. This data was recently presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31-June 4 in Chicago (Abstract 5507).
While additional research is needed to confirm a causal relationship, targeted health services and public health interventions are warranted to “stabilize and ultimately reverse the concomitantly rising rates of obesity and endometrial cancer,” according to the researchers.
June 3, 2024
Read moreE7386, a first-in-class anticancer agent, is currently being investigated in combination with lenvatinib in the open-label, global, Phase Ib Study 102 (NCT04008797). During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the research team described the ongoing, dose-expansion part of Study 102 in patients
June 1, 2024
Read morePhase II data demonstrated durable responses among patients with advanced or recurrent endometrial cancer who underwent treatment with a combination of abemaciclib and fulvestrant. These findings were recently presented by Angela Green, MD, Gynecologic Oncologist at Memorial Sloan Kettering Cancer Center, during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 5511).
June 1, 2024
Read moreNew data revealed the increasing use of fertility-preserving hormonal therapy among patients with early-stage endometrial cancer who are of reproductive age. Younger age, more recent year of diagnosis, non-White race, lower tumor grade, and earlier stage of disease were all associated with the use of hormonal therapy.
June 3, 2024
Read moreBlack women with endometrial cancer face delayed diagnosis and less use of surgery-based treatments compared to White and Asian women, contributing to a significant survival disparity among these racial and ethnic groups in the United States, according to a study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 5608). Results suggest that clinicians and policymakers could help bridge this survival gap, at least in part, by improving access to earlier diagnosis and treatment options regardless of race or ethnicity, the researchers said.
June 3, 2024
Read moreImlunestrant, alone or in combination with abemaciclib, is a safe and tolerable treatment option for patients with metastatic estrogen receptor (ER)-positive endometrioid endometrial cancer, according to findings recently presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 5589).
June 4, 2024
Read moreA recent research effort aimed to better understand the treatment approaches taken by health care providers for the management of advanced endometrial cancer, and how they aligned with current expert recommendations. Findings from this analysis were presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 5613).
June 4, 2024
Read moreNew findings showed that vibostolimab coformulated with pembrolizumab (vibo/pembro) led to durable anti-tumor activity and had a manageable safety profile among patients with previously treated, advanced mismatch repair–deficient (dMMR) endometrial cancer.
June 4, 2024
Read moreA retrospective analysis of advanced endometrial cancer patients revealed racial/ethnic inequities in treatment initiation, biomarker testing, and clinical trial participation. This data, which was recently presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, suggests that clinical trial inequities were partly explained by structural racism and social determinants of health (SDOH) factors, according to the study authors (Abstract 1602).
June 1, 2024
Read more